/Companies

Infinant Health

Sacramento, US · Founded 2011 · Delaware corporation · 8 known investors

Find your way into Infinant Health

Sign up to see every warm intro you have to Infinant Health

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Infinant Health team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Infinant Health develops probiotic products based on B. infantis strains that work with breast milk to support the infant gut microbiome, including its INF108 drug strain aimed at preventing necrotizing enterocolitis (NEC) in premature infants. The company operates in the infant health and microbiome therapeutics space.

Founders & leadership

DJDavid J. Kyle
David J. KyleCo-founderDavid J. Kyle led research and commercial development at Martek Biosciences for over 15 years, where the company developed DHA and ARA ingredients for infant formulas before being acquired in 2011 for over $1B; he subsequently founded Advanced BioNutrition and joined Evolve Biosystems in 2013 as CEO, overseeing five venture capital rounds totaling $136M and the launch of the Evivo product line for infants.
JB
J. Bruce GermanCo-founder
DMDavid Mills
David MillsFounderDavid Mills is a Distinguished Professor of Food Science & Technology at UC Davis whose research focuses on the molecular biology and ecology of gut bacteria and bacterial genomics. He co-founded Infinant Health, which develops probiotic therapeutics based on B. infantis strains for infant microbiome health.
CLCarlito Lebrilla
Carlito LebrillaFounder
DBDaniela Barile
Daniela BarileFounder
SFSamara Freeman
Samara FreemanFounder & Executive Director, Regulatory Affairs & Intellectual Property
MJ
Michael JohnsonExecutive
JC
John CampbellExecutive
JCJames Campbell
James CampbellCFO and Strategic Advisor2013–2016James Campbell is a biotechnology executive with a PhD in plant biochemistry from Deakin University and postdoctoral research at CERMAV CNRS in France, followed by roles as a research scientist at CSIRO and COO/CFO of ChemGenex Pharmaceuticals (ASX/NASDAQ-listed), where he supported growth from $10M to a $230M acquisition. He was a founding executive at Evolve Biosystems and has served as CEO of Patrys Limited and currently as CEO of Imitex Pty Ltd.
BG
Bruce German, PhDFounder
MJ
Mike JohnsonChief Executive Officer

Board

LS
Laura StoppelBoard director

Investors · 8

Reported raises · per SEC filings

Form D private placements

$48.2M disclosed across 2 rounds · 2015–2026

▶$39.2MraisedJun 2026 · 29 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Laura StoppelDirector
  • Michael JohnsonExecutive Officer, Director
  • Mike LiangDirector
  • Amanda Birdsey-BensonDirector
  • Roger WyseDirector
  • Patrick EnrightDirector
  • Katharine KnobilDirector
Offering amount
$118.2M
Amount sold
$39.2M
First sale
May 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$9MraisedAug 2015 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Daniel JanneyDirector
  • John CampbellExecutive Officer
  • J. Bruce GermanDirector
  • James CampbellExecutive Officer
  • David MillsExecutive Officer
  • Catherine MackeyDirector
  • David J. KyleExecutive Officer, Director
  • Anne LoDirector
  • Simon BarnesDirector
Offering amount
$9M
Amount sold
$9M
First sale
Jul 2015
Incorporated
Corporation, Delaware, 2011
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 5

Companies working in the same space as Infinant Health.

Frequently asked questions

What does Infinant Health do?
Infinant Health develops probiotic products based on B. infantis strains that work with breast milk to support the infant gut microbiome, including its INF108 drug strain aimed at preventing necrotizing enterocolitis (NEC) in premature infants. The company operates in the infant health and microbiome therapeutics space.
Who founded Infinant Health?
Infinant Health was founded by David J. Kyle, J. Bruce German, David Mills, Carlito Lebrilla, Daniela Barile, Samara Freeman in 2011.
Who are Infinant Health's investors?
Infinant Health's investors include Acre Venture Partners, Bow Capital, Horizons Ventures, iSelect Fund, Longitude Capital, Spruce Capital Partners, Xeraya Capital, Bill & Melinda Gates Foundation.
How much funding has Infinant Health raised?
Infinant Health has disclosed $48.2M raised across 2 rounds.
Where is Infinant Health headquartered?
Infinant Health is headquartered in Sacramento, US.